Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
1.410
-0.050 (-3.42%)
Oct 24, 2024, 4:00 PM EDT - Market closed
Atossa Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Net Income | -25.91 | -30.09 | -26.96 | -20.61 | -17.83 | -17.24 | |
Depreciation & Amortization | 0.03 | 0.02 | 0.01 | 0.02 | 0.05 | 0.05 | |
Loss (Gain) From Sale of Assets | 0 | - | - | - | - | - | |
Loss (Gain) From Sale of Investments | - | 2.99 | - | - | - | - | |
Stock-Based Compensation | 2.21 | 4.62 | 6.79 | 5.27 | 3.02 | 8.84 | |
Other Operating Activities | - | - | 0 | - | 3.3 | 0.01 | |
Change in Accounts Payable | 0.03 | -2.16 | 1.25 | 0.13 | 1.3 | -0.06 | |
Change in Other Net Operating Assets | 4.95 | 3.68 | -1.85 | -1.28 | -1.41 | -0.73 | |
Operating Cash Flow | -18.68 | -20.94 | -20.76 | -16.47 | -11.57 | -9.13 | |
Capital Expenditures | -0.01 | -0.01 | -0.03 | -0.01 | -0.01 | -0.01 | |
Investment in Securities | - | - | -4.7 | - | - | - | |
Investing Cash Flow | -0.01 | -0.01 | -4.73 | -0.01 | -0.01 | -0.01 | |
Issuance of Common Stock | 0.3 | - | - | 113.88 | 33.62 | 11.34 | |
Repurchase of Common Stock | -1.48 | -1.48 | - | -0.57 | -0.01 | - | |
Financing Cash Flow | -1.17 | -1.48 | - | 113.3 | 38.55 | 11.34 | |
Net Cash Flow | -19.86 | -22.43 | -25.49 | 96.82 | 26.97 | 2.2 | |
Free Cash Flow | -18.69 | -20.96 | -20.79 | -16.48 | -11.58 | -9.14 | |
Free Cash Flow Per Share | -0.15 | -0.17 | -0.16 | -0.14 | -1.02 | -1.08 | |
Levered Free Cash Flow | -10.24 | -11.76 | -10.54 | -21.72 | 6.82 | -4.1 | |
Unlevered Free Cash Flow | -10.24 | -11.76 | -10.54 | -21.72 | 6.82 | -4.1 | |
Change in Net Working Capital | -6.64 | -3.22 | 0 | 14.17 | -12.89 | 2.2 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.